My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

GH Research PLC - Ordinary Shares (NQ:GHRS)

22.99 -0.49 (-2.09%)

Delayed Quote Updated: 12:06 PM EDT, Oct 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about GH Research PLC - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know. ↗

July 23, 2026

Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline.

Via The Motley Fool

Get insights into the top gainers and losers of Thursday's pre-market session. ↗

July 16, 2026

Via Chartmill

These Analysts Revise Their Forecasts On GH Research After Q1 Results ↗

May 15, 2026

GH Research (NASDAQ:GHRS) reported a larger loss than expected in Q1. Analysts lowered price targets, stock fell 3.4%. CEO noted progress in GH001 program.

Via Benzinga

These stocks are gapping in today's session ↗

April 20, 2026

Via Chartmill

The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics

March 26, 2026

Today’s Date: March 26, 2026 Introduction As the global mental health crisis reaches unprecedented levels, the pharmaceutical industry has been forced to look beyond traditional SSRIs toward more...

Via Finterra

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

January 05, 2026

Via Chartmill

Why Is GHRS Stock Rising Today? ↗

January 05, 2026

GH Research stated that the FDA has cleared GH001 for a clinical investigation in the U.S.

Via Stocktwits

Wondering what's happening in today's pre-market session? ↗

January 05, 2026

Via Chartmill

GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment ↗

January 05, 2026

GH001 showed symptom improvement, high remission rates, and sustained benefits in a Phase 2b trial for treatment-resistant depression.

Via Stocktwits

Stay updated with the stocks that are on the move in today's after-hours session. ↗

January 02, 2026

Via Chartmill

GH Research PLC (NASDAQ:GHRS) Reports Q3 2025 Earnings Beat and Clinical Progress ↗

November 06, 2025

GH Research Q3 2025 results show a slight EPS beat. The biotech firm is focused on resolving the FDA clinical hold for its GH001 treatment for depression.

Via Chartmill

Topics Earnings

Depression-Focused GH Research Shares Could See Significant Upside: Analyst ↗

October 13, 2025

GH Research's GH001 shows strong Phase 2 results for treatment-resistant depression, with FDA issues nearly resolved and $1.9 billion U.S. potential.

Via Benzinga

This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

October 13, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

July 23, 2025

Via Benzinga

JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

March 20, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 20, 2025

Via Benzinga

These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week ↗

February 10, 2025

These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments.

Via Stocktwits

On Thursday, there are stocks with unusual volume. Let's take a look. ↗

February 06, 2025

Let's explore the current happenings on the US markets on Thursday. Below, you'll find the stocks exhibiting unusual volume in today's session.

Via Chartmill

These stocks have an unusual volume in today's session ↗

February 05, 2025

Discover the stocks with unexpected trading volume in today's session on the US markets.

Via Chartmill

Unusual volume stocks in Tuesday's session ↗

February 04, 2025

In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.

Via Chartmill

Crude Oil Moves Higher; Owens & Minor Shares Plummet ↗

February 03, 2025

Via Benzinga

Dow Falls 150 Points; ISM Manufacturing PMI Rises In January ↗

February 03, 2025

Via Benzinga

Topics Stocks

IDEXX Laboratories Posts Upbeat Results, Joins Stratasys, Saia And Other Big Stocks Moving Higher On Monday ↗

February 03, 2025

Via Benzinga

Why Is GH Research Stock Trading Higher On Monday? ↗

February 03, 2025

GH Research's Phase 2b trial of GH001 for treatment-resistant depression met its primary endpoint, showing significant efficacy and a favorable safety profile.

Via Benzinga

S&P 500 Down Over 1%; Tyson Foods Posts Upbeat Results ↗

February 03, 2025

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

February 03, 2025

Via Benzinga

Why Triumph Group Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket ↗

February 03, 2025

Via Benzinga

Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

January 22, 2025

Via Benzinga

3 Fast-Growing Stocks Analysts See Doubling in Price

November 11, 2024

Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches.

Via MarketBeat

Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week ↗

September 15, 2024

The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come.

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.